PSME2 Antibody Pair

Overview of PSME2 Antibody Pair

The PSME2 antibody pair refers to matched antibodies targeting distinct epitopes of proteasome activator complex subunit 2 (PSME2), a 27 kDa protein critical for immunoproteasome assembly and antigen presentation. These pairs enable quantitative detection of PSME2 in techniques such as sandwich ELISA, Luminex assays, and multiplexed immunofluorescence . PSME2 (also known as PA28β) forms part of the PA28 activator complex, which modulates proteasome cleavage patterns to enhance MHC class I antigen presentation .

Key Applications of PSME2 Antibody Pairs

Cancer Biomarker Studies

• Breast Cancer: High PSME2 expression correlates with immuno-hot tumor microenvironments (TME), PD-L1 levels, and improved immunotherapy response .

  • TCGA data: PSME2 positively associates with TMB (r=0.62), T-cell inflamed score (r=0.58), and immunomodulators (chemokines, MHC) .

  • IHC validation: PSME2/PD-L1 co-expression predicts pathological complete response (pCR) in immunotherapy cohorts .

• Renal Cell Carcinoma: PSME2 knockdown reduces invasion in CAKI-1/786-O cells by upregulating BNIP3-mediated autophagy .

Immunoproteasome Function

• PA28α/β Complex: Murine knockout models (Psme1/Psme2−/−) show defective immunoproteasome assembly and impaired antigen processing .

• Antigen Presentation: PA28β enhances proteasomal cleavage of viral epitopes (e.g., influenza NP) for MHC-I loading .

Clinical and Therapeutic Implications

PSME2 antibody pairs enable:

1. Immune Profiling: Stratification of tumors into immuno-hot vs. immuno-cold subtypes .

2. Drug Development: Screening for PSME2 inhibitors targeting proteasome-mediated autophagy in renal cancer .

3. Diagnostic Assays: Quantifying PSME2 as a complementary biomarker to PD-L1 in immunotherapy trials .

Limitations and Future Directions

• Species Cross-Reactivity: Most antibodies lack validation in non-mammalian models .

• Standardization: Inter-lot variability observed in polyclonal reagents (e.g., ab187528) .

• Emerging Applications: PSME2’s role in neurodegenerative diseases remains unexplored .